Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MAGNESIUM IN THE PROPHYLAXIS OF MIGRAINE - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Autore:
PFAFFENRATH V; WESSELY P; MEYER C; ISLER HR; EVERS S; GROTEMEYER KH; TANERI Z; SOYKA D; GOBEL H; FISCHER M;
Indirizzi:
LEOPOLDSTR 59-2 D-80802 MUNICH GERMANY NEUROL PRACTICE MUNICH GERMANY UNIV VIENNA,DEPT NEUROL VIENNA AUSTRIA NEUROL PRACTICE BADEN SWITZERLAND UNIV ZURICH,DEPT NEUROL ZURICH SWITZERLAND UNIV MUNSTER,DEPT NEUROL D-4400 MUNSTER GERMANY CHRISTIAN ALBRECHTS UNIV KIEL,DEPT NEUROL KIEL GERMANY CLIN PSYCHOSOMAT & NEUROL DUISBURG GERMANY INST NUMER STAT COLOGNE GERMANY
Titolo Testata:
Cephalalgia
fascicolo: 6, volume: 16, anno: 1996,
pagine: 436 - 440
SICI:
0333-1024(1996)16:6<436:MITPOM>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
SPREADING DEPRESSION; PROPRANOLOL; HEADACHE; SERUM;
Keywords:
EFFICACY; MAGNESIUM; MIGRAINE PROPHYLAXIS; SAFETY; TOLERABILITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
V. Pfaffenrath et al., "MAGNESIUM IN THE PROPHYLAXIS OF MIGRAINE - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY", Cephalalgia, 16(6), 1996, pp. 436-440

Abstract

The migraine prophylactic effect of 10 mmol magnesium twice-daily hasbeen evaluated in a multicentre, prospective, randomized, double-blind, placebo-controlled study. Patients with two to six migraine attacksper month without aura, and history of migraine of at least 2 years, were included. A 4-week baseline period without medication was followed by 12 weeks of treatment with magnesium or placebo. The primary efficacy end-point was a reduction of at least 50% in intensity or duration of migraine attacks in hours at the end of the 12 weeks of treatmentcompared to baseline. With a calculated total sample size of 150 patients, an interim analysis was planned after completing treatment of atleast 60 patients, which in fact was performed with 69 patients (64F,5M), aged 18-64 years. Of these, 35 had received magnesium and 34 placebo. The number of responders was 10 in each group (28.6% under magnesium and 29.4% under placebo). As determined in the study protocol, this was a major reason to discontinue the trial. With regard to the number of migraine days or migraine attacks there was no benefit with magnesium compared to placebo. There were no centre-specific differences,and the final assessments of treatment efficacy by the doctor and patient were largely equivocal. With respect to tolerability and safety, 45.7% of patients in the magnesium group reported primarily mild adverse events like soft stool and diarrhoea in contrast to 23.5% in the placebo group.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 18:18:22